large B-cell lymphoma

Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
FDA advisers question efficacy of Roche’s Polivy in first line LBCL
FDA advisers question efficacy of Roche’s Polivy in first line LBCL
BioSpace
Roche
Genentech
Polivy
LBCL
large B-cell lymphoma
Flag link:
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
BioSpace
Bristol Myers Squibb
CAR-T
Breyanzi
liso-cel
FDA
large B-cell lymphoma
Flag link:
AbbVie preps filings for lymphoma bispecific licensed from Genmab
AbbVie preps filings for lymphoma bispecific licensed from Genmab
Pharmaforum
AbbVie
Genmab
cancer
epcoritamab
large B-cell lymphoma
Flag link:
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Pharmaforum
Gilead Sciences
Kite Pharma
CAR-T
Bristol Myers Squibb
lymphoma
large B-cell lymphoma
Flag link:
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
Pharmaforum
Bristol Myers Squibb
CAR-T
Breyanzi
large B-cell lymphoma
Novartis
Gilead Sciences
FDA
Flag link:
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Endpoints
CAR-T
Gilead Sciences
Pfizer
utomilumab
Yescarta
large B-cell lymphoma
Flag link:
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Fierce Pharma
Gilead Sciences
Kite Pharma
Novartis
CAR-T
FDA
axi-cel
Yescarta
non-Hodgkin's lymphoma
large B-cell lymphoma
Flag link:
Late-stage study of Roche's Gazyva in large B-cell lymphoma fails to hit main goal
Late-stage study of Roche's Gazyva in large B-cell lymphoma fails to hit main goal
First Word Pharma
Roche
Gazyva
large B-cell lymphoma
clinical trials
Flag link:
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint
The Fly on the Wall
GSK
Genmab
ofatumumab
large B-cell lymphoma
Flag link:
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers
Yahoo/BusinessWire
large B-cell lymphoma
lymphoma
leukemia
T-cell acute lymphoblastic leukemia
IPI-145
Infinity Pharmaceuticals
Flag link: